Generics - Production, Daiichi Sankyo

Filter

Current filters:

ProductionDaiichi Sankyo

Popular Filters

Another ban by US FDA on a Ranbaxy production facility

Another ban by US FDA on a Ranbaxy production facility

24-01-2014

As if the Indian drug major has not had enough negative news from the US regulator, the US Food and Drug…

Asia-PacificDaiichi SankyoGenericsIndiaNorth AmericaProductionRanbaxy LaboratoriesRegulationUSA

Ban on FDA-regulated drugs from Ranbaxy's Mohali plant

17-09-2013

There was another blow for India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) yesterday (September…

Asia-PacificDaiichi SankyoGenericsNorth AmericaProductionRanbaxy LaboratoriesRegulation

Ranbaxy highlights its actions on improved business and quality assurance

23-05-2013

Indian drugmaker Ranbaxy Laboratories (BSE: 500359), whose US subsidiary was the subject of the biggest…

Daiichi SankyoGenericsManagementProductionRanbaxy LaboratoriesRegulation

US DoJ says Ranbaxy pleads guilty and agrees to pay $500 million in settlements

14-05-2013

In the largest drug safety settlement to date with a generic drug manufacturer, Ranbaxy USA, a subsidiary…

Asia-PacificDaiichi SankyoFinancialGenericsLegalNorth AmericaProductionRanbaxy LaboratoriesRegulation

Ranbaxy gains approval for new manufacturing plant in Malaysia

14-09-2012

India's largest drugmaker Ranbaxy Laboratories (AB: BO). said yesterday that the government of Malaysia…

Asia-PacificDaiichi SankyoGenericsProductionRanbaxy Laboratories

Parexel

Parexel

Back to top